Juan Flores-Montero

TL;DR: The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

TL;DR: The 6 years of extensive collaborative experiments and the analysis of hundreds of cell samples of patients and healthy controls have provided for the first time laboratory protocols and software tools for fully standardized 8-color flow cytometric immunophenotyping of normal and malignant leukocytes in bone marrow and blood; this has yielded highly comparable data sets, which can be integrated in a single database.

TL;DR: EuroFlow-based NGF is established as a highly sensitive, fully standardized approach for MRD detection in MM which overcomes the major limitations of conventional flow-MRD methods and is ready for implementation in routine diagnostics.

TL;DR: Overall, consensus exists about the utility of combined assessment of CD38 and CD138 for the identification of BM plasma cells (PC); in contrast, more heterogeneous lists of markers are used to further distinguish between normal/reactive PCs and myeloma PCs in the MRD settings.

TL;DR: The IMWG flow MRD-negative response criterion is highly applicable and sensitive to evaluate treatment efficacy in multiple myeloma and overcame poor prognostic features at diagnosis, including high-risk cytogenetics.